Claims
- 1. A compound of the formula: ##STR17## wherein R.sub.5 is C.sub.1 -C.sub.6 -loweralkyl and R.sub.7 is independently selected at each occurrence from unsubstituted pyridyl and pyridyl which is substituted with C.sub.1 -C.sub.6 -loweralkyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino, N-protected amino, C.sub.1 -C.sub.6 -alkylamino, (N-protected)-C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino or halo; or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the acyl residue of the ester is (i) R*C(O)-- or R*C(S)-- wherein R* is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -thioalkoxy, C.sub.1 -C.sub.6 -alkoxy-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -thioalkoxy-C.sub.1 -C.sub.6 -alkyl or C.sub.1 -C.sub.6 -haloalkoxy, (ii) R.sub.a --C(R.sub.b)(R.sub.d)--C(O)-- or R.sub.a --C(R.sub.b)(R.sub.d)--C(S)-- wherein R.sub.b and R.sub.d are independently selected from hydrogen and C.sub.1 -C.sub.6 -loweralkyl and R.sub.a is --N(R.sub.e)(R.sub.f), --OR.sub.e or --SR.sub.e wherein R.sub.e and R.sub.f are independently selected from hydrogen, C.sub.1 -C.sub.6 -loweralkyl and C.sub.1 -C.sub.6 -haloalkyl, (iii) R.sub.180 NH(CH.sub.2).sub.2 NHCH.sub.2 C(O)-- or R.sub.180 NH(CH.sub.2).sub.2 OCH.sub.2 C(O)-- wherein R.sub.180 is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, aryl-C.sub.1 -C.sub.6 alkyl wherein the aryl group is phenyl, naphthyl, tetrahydronaphtyl, indanyl or indenyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkanoyl or benzoyl, (iv) H.sub.2 O.sub.3 P-- or (v) --C(O)CH.sub.2 CH.sub.2 COOH and wherein the prodrug is a compound wherein the hydroxy group is functionalized with a substituent of the formula --CH(R.sub.g)OC(O)R.sub.181 or --CH(R.sub.g)OC(S)R.sub.181 wherein R.sub.181 is C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -thioalkoxy or C.sub.1 -C.sub.6 -haloalkoxy and R.sub.g is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxycarbonyl, aminocarbonyl, C.sub.1 -C.sub.6 -alkylaminocarbonyl or di-(C.sub.1 -C.sub.6 -alkyl)aminocarbonyl.
- 2. The compound of claim 1 wherein R.sub.7 is independently selected at each occurrence from 2-pyridyl, 3-pryidyl and 4-pyridyl.
- 3. A compound of the formula: ##STR18## wherein R.sub.7 is independently selected at each occurrence from unsubstituted pyridyl and pyridyl which is substituted with C.sub.1 -C.sub.6 -loweralkyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino, N-protected amino, C.sub.1 -C.sub.6 -alkylamino, (N-protected)-C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino or halo; or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the acyl residue of the ester is (i) R*C(O)-- or R*C(S)-- wherein R* is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -thioalkoxy, C.sub.1 -C.sub.6 -alkoxy-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -thioalkoxy-C.sub.1 -C.sub.6 -alkyl or C.sub.1 -C.sub.6 -haloalkoxy, (ii) R.sub.a --C(R.sub.b)(R.sub.d)--C(O)-- or R.sub.a --C(R.sub.b)(R.sub.d)--C(S)-- wherein R.sub.b and R.sub.d are independently selected from hydrogen and C.sub.1 -C.sub.6 -loweralkyl and R.sub.a is --N(R.sub.e)(R.sub.f), --OR.sub.e or --SR.sub.e wherein R.sub.e and R.sub.f are independently selected from hydrogen, C.sub.1 -C.sub.6 -loweralkyl and C.sub.1 -C.sub.6 -haloalkyl, (iii) R.sub.180 NH(CH.sub.2).sub.2 NHCH.sub.2 C(O)-- or R.sub.180 NH(CH.sub.2).sub.2 OCH.sub.2 C(O)-- wherein R.sub.180 is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, aryl-C.sub.1 -C.sub.6 -alkyl wherein the aryl group is phenyl, naphthyl, tetrahydronaphthyl, indanyl or indenyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkanoyl or benzoyl, (iv) H.sub.2 O.sub.3 P-- or (v) --C(O)CH.sub.2 COOH and wherein the prodrug is a compound wherein the hydroxy group is functionalized with a substituent of the formula --CH(R.sub.g)OC(O)R.sub.181 or --CH(R.sub.g)OC(S)R.sub.181 wherein R.sub.181 is C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -thioalkoxy or C.sub.1 -C.sub.6 -haloalkoxy and R.sub.g is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxycarbonyl, aminocarbonyl, C.sub.1 -C.sub.6 -alkylaminocarbonyl or di-(C.sub.1 -C.sub.6 -alkyl)aminocarbonyl.
- 4. A compound of the formula: ##STR19## wherein R.sub.7 is independently selected at each occurrence from 2-pyridyl, 3-pyridyl and 4-pyridyl; or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the acyl residue of the ester is (i) R*C(O)-- or R*C(S)-- wherein R* is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -thioalkoxy, C.sub.1 -C.sub.6 -alkoxy-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -thioalkoxy-C.sub.1 -C.sub.6 -alkyl or C.sub.1 -C.sub.6 -haloalkoxy, (ii) R.sub.a --C(R.sub.b)(R.sub.d)--C(O)-- or R.sub.a --C(R.sub.b)(R.sub.d)--C(S)-- wherein R.sub.b and R.sub.d are independently selected from hydrogen and C.sub.1 -C.sub.6 -loweralkyl and R.sub.a is --N(R.sub.e)(R.sub.f), --OR.sub.e or --SR.sub.e wherein R.sub.e and R.sub.f are independently selected from hydrogen, C.sub.1 -C.sub.6 -loweralkyl and C.sub.1 -C.sub.6 -haloalkyl, (iii) R.sub.180 NH(CH.sub.2).sub.2 NHCH.sub.2 C(O)-- or R.sub.180 NH(CH.sub.2).sub.2 OCH.sub.2 C(O)-- wherein R.sub.180 is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, aryl-C.sub.1 -C.sub.6 -alkyl wherein the aryl group is phenyl, naphthyl, tetrahydronaphthyl, indanyl or indenyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkanoyl or benzoyl, (iv) H.sub.2 O.sub.3 P-- or (v) --C(O)CH.sub.2 CH.sub.2 COOH and wherein the prodrug is a compound wherein the hydroxy group is functionalized with a substituent of the formula --CH(R.sub.g)OC(O)R.sub.181 or --CH(R.sub.g)OC(S)R.sub.181 wherein R.sub.181 is C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -thioalkoxy or C.sub.1 -C.sub.6 -haloalkoxy and R.sub.g is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxycarbonyl, aminocarbonyl, C.sub.1 -C.sub.6 -alkylaminocarbonyl or di-(C.sub.1 -C.sub.6 -alkyl)aminocarbonyl.
- 5. A compound selected from the group consisting of: (2S,3S,5S)-2-(N-(N-((2-pyridinyl)methoxycarbonyl)-isoleucinyl)amino)-5-(N-((3-pyridinyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-2-(N-((6-Methylpyridin-2yl)methoxycarbonyl-valinylamino)-5-(N-((pyridin-3-yl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-2-(N-((6-Methylpyridin-3-yl)methoxycarbonyl-valinylamino)-5-(N-(pyridin-3-yl)methoxycarbonyl)amino-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-2-(N-((5-Methyl-3-pyridinyl)-methoxycarbonyl)valinyl)amino)-5-(N-(3-pyridinyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; and (2S,3S,5S)-2-(N-((6-Methoxy-3-pyridinyl)methoxycarbonyl)valinyl)amino)-5-(N-(3-pyridinyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the acyl residue of the ester is (i) R*C(O)-- or R*C(S)-- wherein R* is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -thioalkoxy, C.sub.1 -C.sub.6 -alkoxy-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -thioalkoxy-C.sub.1 -C.sub.6 -alkyl or C.sub.1 -C.sub.6 -haloalkoxy, (ii) R.sub.a --C(R.sub.b)(R.sub.d)--C(O)-- or R.sub.a --C(R.sub.b)(R.sub.d)--C(S)-- wherein R.sub.b and R.sub.d are independently selected from hydrogen and C.sub.1 -C.sub.6 -loweralkyl and R.sub.a is --N(R.sub.e)(R.sub.f), --OR.sub.e or --SR.sub.e wherein R.sub.e and R.sub.f are independently selected from hydrogen, C.sub. 1 -C.sub.6 -loweralkyl and C.sub.1 -C.sub.6 -haloalkyl, (iii) R.sub.180 NH(CH.sub.2).sub.2 NHCH.sub.2 C(O)-- or R.sub.180 NH(CH.sub.2).sub.2 OCH.sub.2 C(O)-- wherein R.sub.180 is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, aryl-C.sub.1 -C.sub.6 -alkyl wherein the aryl group is phenyl, naphthyl, tetrahydronaphthyl, indanyl or indenyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkanoyl or benzoyl, (iv) H.sub.2 O.sub.3 P-- or (v) --C(O)CH.sub.2 CH.sub.2 COOH and wherein the prodrug is a compound wherein the 3-hydroxy group is functionalized with a substituent of the formula --CH(R.sub.g)OC(O)R.sub.181 or --CH(R.sub.g)OC(S)R.sub.181 wherein R.sub.181 is C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -thioalkoxy or C.sub.1 -C.sub.6 -haloalkoxy and R.sub.g is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxycarbonyl, aminocarbonyl, C.sub.1 -C.sub.6 -alkylaminocarbonyl or di-(C.sub. 1 -C.sub.6 -alkyl)aminocarbonyl.
- 6. (2S,3S,5S)-2-(N-(N-((2-Pyridinyl)methoxycarbonyl)-valinyl)amino)-5-(N-((3-pyridinyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the acyl residue or the ester is (i) R*C(O)-- or R*C(S)-- wherein R* is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -thioalkoxy, C.sub.1 -C.sub.6 -alkoxy-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -thioalkoxy-C.sub.1 -C.sub.6 -alkyl or C.sub.1 -C.sub.6 -haloalkoxy, (ii) R.sub.a --C(R.sub.b)(R.sub.d)--C(O)-- or R.sub.a --C(R.sub.b)(R.sub.d)--C(S)-- wherein R.sub.b and R.sub.d are independently selected from hydrogen and C.sub.1 -C.sub.6 -loweralkyl and R.sub.a is --N(R.sub.e)(R.sub.f), --OR.sub.e or --SR.sub.e wherein R.sub.e and R.sub.f are independently selected from hydrogen, C.sub.1 -C.sub.6 -loweralkyl and C.sub.1 -C.sub.6 -haloalkyl, (iii) R.sub.180 NH(CH.sub.2).sub.2 NHCH.sub.2 C(O)-- or R.sub.180 NH(CH.sub.2).sub.2 OCH.sub.2 C(O)-- wherein R.sub.180 is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, aryl-C.sub.1 -C.sub.6 -alkyl wherein the aryl group is phenyl, naphthyl, tetrahydronaphthyl, indanyl or indenyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkanoyl or benzoyl, (iv) H.sub.2 O.sub.3 P-- or (v) --C(O)CH.sub.2 CH.sub.2 COOH and wherein the prodrug is a compound wherein the 3-hydroxy group is functionalized with a substituent of the formula --CH(R.sub.g)OC(O)R.sub.181 or --CH(R.sub.g)OC(S)R.sub.181 wherein R.sub.181 is C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -thioalkoxy or C.sub.1 -C.sub.6 -haloalkoxy and R.sub.g is hydrogen, C.sub.1 -C.sub.6 -loweralkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.1 -C.sub.6 -alkoxycarbonyl, aminocarbonyl, C.sub.1 -C.sub.6 -alkylaminocarbonyl or di-(C.sub.1 -C.sub.6 -alkyl)aminocarbonyl.
- 7. (2S,3S,5S)-2-(N-(N-((2-Pyridinyl)methoxycarbonyl)-valinyl)amino)-5-(N-(3-pyridinyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt thereof.
Parent Case Info
This is a continuation of U.S. patent application Ser. No. 777,626, filed Oct. 23, 1991 now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 746,020, filed Aug. 15, 1991, now abandoned which is a continuation-in-part of U.S. patent application Ser. No. 616,170, filed Nov. 20, 1990, now abandoned which is a continuation-in-part of U.S. patent application Ser. No. 518,730, filed May 9, 1990, now U.S. Pat. No. 5,142,056 issued Aug. 25, 1992 which is a continuation-in-part of U.S. patent application Ser. No. 456,124, filed Dec. 22, 1989, now abandoned which is a continuation-in-part of U.S. patent application Ser. No. 405,604, filed Sep. 8, 1989, now abandoned which is a continuation-in-part of U.S. patent application Ser. No. 355,945, filed May 23, 1989 now abandoned.
Foreign Referenced Citations (7)
Number |
Date |
Country |
393445 |
Oct 1990 |
EPX |
402646 |
Dec 1990 |
EPX |
428849 |
May 1991 |
EPX |
441192 |
Aug 1991 |
EPX |
3829594 |
Mar 1990 |
DEX |
4003575 |
Aug 1991 |
DEX |
WO8802374 |
Apr 1988 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Zeffren et al. The Study of Enzyme Mechanism p. 87 1974. |
Wade Jr. Organic Chemistry p. 349 1987. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
777626 |
Oct 1991 |
|
Continuation in Parts (6)
|
Number |
Date |
Country |
Parent |
746020 |
Aug 1991 |
|
Parent |
616170 |
Nov 1990 |
|
Parent |
518730 |
May 1990 |
|
Parent |
456124 |
Dec 1989 |
|
Parent |
405604 |
Sep 1989 |
|
Parent |
355945 |
May 1989 |
|